

Haematologica  
HAEMATOL/2019/236083  
Version 3

Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.

Tatiana Raskovalova, Patrick B. Deegan, Pramod K. Mistry, Elena Pavlova, Ruby Yang, Ari Zimran, Juliette Berger, Céline Bourgne, Bruno Pereira, José Labarère, and Marc G. Berger

Disclosures: 1. This research has received no specific grant from any funding agency from the public, commercial, or not-for-profit sectors. 2. Patrick Deegan received speaker and board membership fees from Takeda and consulting fees from Sanofi Corporation. Pramod Mistry received research grant, lecture fee honoraria, and travel support from Sanofi-Genzyme. Ari Zimran received consulting fees from Shire and Preval Therapeutics, honoraria from Shire Corporation and Pfizer, he is an employee at the Gaucher Clinic, Shaare Zedek Medical Center, Israel, which received research grants from Shire Corporation, Centogene and Pfizer, and support from Shire Corporation, Pfizer and Sanofi-Genzyme for participation in their respective registries (GOS, TALIAS and ICGG). Marc G Berger received speaker fees and unrestricted research grants from Sanofi-Genzyme and Shire Corporation. The other authors have no conflict of interest relevant to this study.

Contributions: TR contributed to the study design, data acquisition, interpretation of the results, and manuscript preparation. PD, EP, PM, RY, AZ, JB, CB contributed to data acquisition and manuscript preparation. BP and JL contributed to the study design, data acquisition, data management, statistical analysis, interpretation of the results, and manuscript preparation. MB provided project leadership, contributed to the interpretation of the results, and manuscript preparation. All authors approved the final version of the manuscript.